ERNA Latest Headlines

ERNA-101 Phase 1 Study Planned for Q4 2026: Complete Tumor Clearance in Preclinical Ovarian Cancer Models

Market Chameleon (Wed, 15-Jul 9:52 AM)

ERNA-101 Combination Therapy Achieves 67% Complete Tumor Clearance in Independent Ovarian Cancer Study

Market Chameleon (Wed, 15-Jul 8:10 AM)

Ernexa’s ERNA-101 Moves Closer to Clinical Trials: GMP Manufacturing Complete, IND Submission Expected in Q3 2026

Market Chameleon (Wed, 17-Jun 9:18 AM)

ERNA-101 Shows Promising Results in Ovarian Cancer—Clinical Data Reveals 100% Survival in Preclinical Studies

Market Chameleon (Tue, 12-May 11:14 AM)

ERNA-101 Shows Complete Tumor Elimination and 100% Survival in Ovarian Cancer Models—What Sets Ernexa Therapeutics Apart?

Market Chameleon (Mon, 11-May 9:21 AM)

ERNA-101 Shows Complete Tumor Clearance and 100% Survival in Preclinical Ovarian Cancer Models

Market Chameleon (Thu, 7-May 11:31 AM)

ERNA-101 Achieves 100% Survival and Tumor Elimination in Ovarian Cancer Models—A Turning Point for Immunotherapy?

Market Chameleon (Wed, 6-May 9:53 AM)

ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models—Could This Redefine Treatment Expectations?

Market Chameleon (Wed, 6-May 9:08 AM)